[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypofractionated-radiotherapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypofractionated-radiotherapy":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,74,98],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":5},"100606977","phase-1-hypofractionated-radiotherapy-plus-immunochemotherapy-for-neoadjuvant-treatment-of-gastroesophageal-junction-adenocarcinoma-100606977",false,"NCT07182565","Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma","A Phase Ib\u002FII Study of Hypofractionated Radiotherapy Combined With Immunochemotherapy as Neoadjuvant Treatment for Adenocarcinoma of the Gastroesophageal Junction","Inclusion Criteria:\n\n1. Histologically and\u002For cytologically confirmed diagnosis of locally advanced adenocarcinoma of the gastroesophageal junction (GEJ) (Siewert types I-III), defined as cT3-4, any N, M0 or cT2 N+, M0 according to the 8th edition of the AJCC staging system.\n2. Determined as resectable locally advanced disease after multidisciplinary team (MDT) evaluation.\n3. Age ≥18 years, regardless of sex.\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n5. Estimated life expectancy ≥3 months.\n6. No prior anti-cancer treatment.\n7. At least one measurable lesion as defined by RECIST v1.1 (lesion diameter ≥1 cm on spiral CT or ≥2 cm on standard CT or MRI), assessed within 28 days prior to enrollment.\n8. Adequate organ function within 14 days prior to treatment, defined as follows (note: blood transfusions, platelet infusions, or G-CSF use not permitted within 14 days prior to hematologic assessment):\n\n1\\) Hematological: Hemoglobin ≥9 g\u002FdL (without recent transfusion); ANC ≥1.5 × 10⁹\u002FL; WBC ≥3.0 × 10⁹\u002FL (no G-CSF use); Platelets ≥75 × 10⁹\u002FL (no IL-11 or TPO use).\n\n2\\) Biochemistry: Total bilirubin ≤1.5 × ULN; AST and ALT ≤2.5 × ULN; Serum creatinine ≤1.5 × ULN or creatinine clearance ≥60 mL\u002Fmin (Cockcroft-Gault formula); Serum albumin ≥25 g\u002FL.\n\n3\\) Coagulation: INR \\\u003C1.5, APTT \\\u003C1.5 × ULN within 7 days before enrollment; PT ≤1.5 × ULN.\n\n9.Patients with active hepatitis B or C infection must have received antiviral therapy ≥14 days prior to enrollment, with HBV DNA ≤500 IU\u002FmL or 2500 copies\u002FmL, HCV RNA undetectable, and agree to continue antiviral therapy during the study.\n\n10.LVEF ≥50% on echocardiography. 11.Women of childbearing potential must have a negative pregnancy test (serum or urine) within 7 days prior to enrollment and agree to use effective contraception during the study and for at least 3 months after the last dose. Males must use effective contraception during and for at least 3 months after treatment. Female participants must not be breastfeeding or donate\u002Fretrieve ova within 60 days after the last dose.\n\n12.Willing and able to provide written informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n1. Confirmed dMMR or MSI-H by immunohistochemistry or genetic testing.\n2. Evidence of peritoneal or visceral metastasis (based on thoracoabdominal CT, bone scan, or MRI if bone metastasis is suspected).\n3. Other malignancies within the past 5 years, except cured basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix.\n4. Known allergy or hypersensitivity to any study drugs or their excipients; contraindications to study drugs.\n5. Clinically significant upper gastrointestinal bleeding within 30 days before enrollment or randomization.\n6. Interstitial lung disease, pulmonary fibrosis, active tuberculosis, or steroid-requiring pneumonitis confirmed by CT.\n7. Active autoimmune or inflammatory disease requiring immunosuppressants within 2 years (e.g., IBD, SLE, sarcoidosis, Wegener's, MG, Graves', rheumatoid arthritis, etc.); exceptions: well-controlled type 1 diabetes, hypothyroidism under hormone replacement, untreated localized skin diseases (e.g., vitiligo, psoriasis).\n8. Immunodeficiency, history of HIV infection or organ transplantation.\n9. Active HBV (HBsAg positive) or HCV infection. Previously treated or well-controlled HBV\u002FHCV is allowed.\n10. Systemic corticosteroids or immunosuppressants within 2 weeks prior to treatment. Exceptions: inhaled or local steroids, adrenal replacement (\\\u003C10 mg\u002Fday prednisone equivalent), or short-term corticosteroids (\\\u003C7 days) for prophylaxis or non-autoimmune indications.\n11. Uncontrolled comorbidities, including:\n\n1）Poorly controlled hypertension (SBP ≥150 mmHg or DBP ≥100 mmHg); 2）Grade II+ myocardial ischemia or MI within 6 months, arrhythmia (QT ≥480 ms, AF), uncontrolled angina, CHF (NYHA III-IV), valvular disease, cardiomyopathy, stroke or TIA history; 3）Active or uncontrolled infection; 4）Liver disease (cirrhosis, decompensation, active hepatitis); 5）Poorly controlled diabetes (FBG \\>10 mmol\u002FL); 6）Proteinuria ≥++ or 24h urine protein \\>1.0 g. 12.Coagulation abnormalities (INR \\>1.5 or APTT \\>1.5 × ULN), known bleeding tendency, or patients receiving thrombolytic or anticoagulant therapy. Known congenital or acquired bleeding or thrombotic disorders, such as hemophilia, coagulation defects, thrombocytopenia, hypersplenism, etc.\n\nPatients with significant hemoptysis (≥2.5 mL per day), or a history of clinically significant bleeding (e.g., gastrointestinal bleeding, hemorrhagic gastric ulcers, or fecal occult blood test ≥++) within 3 months prior to enrollment.\n\nPatients requiring long-term anticoagulation with warfarin or heparin, or long-term antiplatelet therapy (aspirin ≥300 mg\u002Fday or clopidogrel ≥75 mg\u002Fday).\n\n13.Major surgery (e.g., craniotomy, thoracotomy, or laparotomy) within 4 weeks prior to first dose, or expected to undergo major surgery during the study, or non-diagnostic surgery within 4 weeks prior to trial initiation.\n\n14.History of gastrointestinal perforation and\u002For fistula within 6 months before enrollment; or history of arterial or venous thromboembolic events, such as stroke (except stable cerebral infarction as judged by the investigator), deep vein thrombosis, or pulmonary embolism.\n\n15.Long-term unhealed wounds or fractures. 16.Severe gastrointestinal conditions that may interfere with oral drug absorption, such as inability to swallow, chronic diarrhea, or intestinal obstruction.\n\n17.Severe malnutrition. 18.Pregnant or lactating women, or participants of reproductive potential (male or female not postmenopausal for at least one year) who are unwilling to use effective contraception.\n\n19.History of substance abuse or uncontrolled psychiatric illness. 20.Unwillingness or inability to comply with study requirements. 21.Participation in another clinical trial within 30 days prior to study entry, or planning to participate in another trial during the study period.\n\n22.Any severe or uncontrolled medical condition, judged by the investigator to potentially compromise patient safety or interfere with study completion.","ALL","18 Years",{"count":19,"type":20},84,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","The purpose of this study is to investigate the safety and efficacy of HFRT plus neoadjuvant ICT in locally advanced resectable GEJA.",[27,28],"Gastroesophageal Junction Adenocarcinoma","Hypofractionated Radiotherapy",[30,31,32,33,34,35],"neoadjuvant therapy","hypofractionated radiotherapy","immunotherapy","chemotherapy","Serplulimab","pCR","RECRUITING","2026-01-03",{"date":39,"type":40},"2026-01-06","ACTUAL",{"date":42,"type":40},"2025-11-18",{"date":44,"type":20},"2029-08-31",{"name":46,"class":47},"West China Hospital","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":5},"100598504","phase-1-hypofractionated-radiotherapy-combined-with-immunochemotherapy-for-conversion-treatment-of-gastroesophageal-junction-adenocarcinoma-100598504","NCT07072351","Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma","A Phase Ib\u002FII Study of Hypofractionated Radiotherapy Combined With Immunochemotherapy as Conversion Therapy for Locally Advanced Gastroesophageal Junction Adenocarcinoma","Inclusion Criteria:\n\nParticipants must meet all of the following criteria:\n\n1. Histologically and\u002For cytologically confirmed diagnosis of locally advanced gastroesophageal junction adenocarcinoma (GEJA), Siewert type I-III, with staging of cT3-4, any N, M0 or cT2 N+, M0, according to the AJCC 8th edition.\n2. Resectable locally advanced disease as determined by multidisciplinary team (MDT) assessment.\n3. Age ≥18 years, regardless of sex.\n4. ECOG performance status of 0 or 1.\n5. Estimated life expectancy of ≥3 months.\n6. No prior anti-tumor therapy.\n7. At least one measurable lesion per RECIST v1.1, defined as:\n\n   * Lesion ≥1 cm in longest diameter on spiral CT, or\n   * Lesion ≥2 cm in longest diameter on conventional CT or MRI.\n   * Imaging must be performed within 28 days prior to enrollment.\n8. Adequate organ function within 14 days prior to treatment, as defined below (Note: No RBC or platelet transfusion or use of G-CSF within 14 days prior to hematology testing):\n\n   Hematologic:\n   * Hemoglobin ≥9 g\u002FdL (without transfusion)\n   * ANC ≥1.5 × 10⁹\u002FL\n   * WBC ≥3.0 × 10⁹\u002FL (without G-CSF)\n   * Platelets ≥75 × 10⁹\u002FL (without IL-11 or TPO)\n\n   Biochemical:\n   * Total bilirubin ≤1.5 × ULN\n   * AST and ALT ≤2.5 × ULN\n   * Serum creatinine ≤1.5 × ULN or creatinine clearance ≥60 mL\u002Fmin (Cockcroft-Gault formula)\n   * Albumin ≥25 g\u002FL (2.5 g\u002FdL)\n\n   Coagulation (within 7 days prior to enrollment):\n   * INR \\\u003C1.5\n   * APTT \\\u003C1.5 × ULN\n   * INR or PT ≤1.5 × ULN\n9. For patients with active hepatitis B or C:\n\n   * Antiviral therapy must be initiated ≥14 days before enrollment\n   * HBV DNA ≤500 IU\u002FmL or ≤2500 copies\u002FmL; HCV RNA undetectable\n   * Must agree to continue antiviral therapy during the study\n10. Left ventricular ejection fraction (LVEF) ≥50% by echocardiography.\n11. Women of childbearing potential:\n\n    * Negative serum or urine pregnancy test within 7 days prior to enrollment\n    * Agree to use effective contraception during the study and for at least 3 months after the last dose\n    * Must not breastfeed or donate\u002Fretrieve ova within 60 days after the last dose\n    * Effective contraception must be continued for at least 6 months after last dose of chemotherapy\n12. Men must be surgically sterile or agree to use effective contraception during the study and for at least 3 months after the last dose.\n13. Voluntarily signed informed consent with good compliance and willingness to complete study procedures and follow-up.\n\nExclusion Criteria:\n\nParticipants who meet any of the following conditions will be excluded:\n\n1. Diagnosed as mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) by immunohistochemistry or gene testing.\n2. Evidence of peritoneal or multi-organ metastatic disease, as confirmed by chest and abdominal CT, bone scan, or MRI (in cases with suspected osseous lesions).\n3. History of or concurrent other malignancies within the past 5 years, excluding cured basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix.\n4. Known allergy to any component of the investigational drugs, history of severe hypersensitivity, or any contraindication to study drugs.\n5. Clinically significant upper gastrointestinal bleeding within 30 days prior to enrollment or randomization.\n6. History of congenital pulmonary fibrosis, drug-induced pneumonitis, active pulmonary tuberculosis, or CT-confirmed active pneumonia; interstitial lung disease requiring steroid treatment.\n7. Active autoimmune or inflammatory diseases requiring immunosuppressive therapy within 2 years prior to treatment, including but not limited to:\n\n   * Inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, diverticulitis),\n   * Systemic lupus erythematosus,\n   * Sarcoidosis,\n   * Tuberculosis,\n   * Wegener's granulomatosis,\n   * Myasthenia gravis,\n   * Graves' disease,\n   * Rheumatoid arthritis,\n   * Hypophysitis,\n   * Uveitis,\n   * Glomerulonephritis,\n   * Nephrotic syndrome,\n   * Fanconi syndrome, or renal tubular acidosis. Exceptions: type 1 diabetes, hypothyroidism controlled by hormone replacement, and non-systemically treated dermatologic conditions (e.g., vitiligo, psoriasis, alopecia).\n8. History of immunodeficiency, HIV infection (positive HIV 1\u002F2 antibodies), congenital or acquired immunodeficiency disorders, or history of organ transplantation.\n9. Active hepatitis B (HBsAg positive) or active hepatitis C infection. Patients with past or controlled HBV\u002FHCV infection may be eligible.\n10. Use of systemic corticosteroids or immunosuppressants within 2 weeks prior to study treatment.\n\n    * Inhaled or topical corticosteroids and adrenal replacement doses (equivalent to ≤10 mg\u002Fday prednisone) are permitted.\n    * Short-term (\\\u003C7 days) corticosteroids are allowed for non-autoimmune conditions or prophylaxis (e.g., contrast allergy).\n11. Uncontrolled or serious comorbidities, including:\n\n    * Poorly controlled hypertension (SBP ≥150 mmHg or DBP ≥100 mmHg despite medication)\n    * Myocardial infarction, ischemia (grade II or above), acute coronary syndrome within 6 months, arrhythmia (e.g., QTc ≥480 ms, atrial fibrillation), or uncontrolled angina\n    * NYHA class III-IV heart failure, LVEF \\\u003C50%, severe valvular disease, cardiomyopathy of any cause\n    * History of stroke or transient ischemic attack within screening period\n    * Active or uncontrolled infection\n    * Severe liver disease (e.g., cirrhosis, decompensated liver disease, chronic active hepatitis) affecting tolerability to treatment\n    * Poorly controlled diabetes (fasting glucose \\>10 mmol\u002FL)\n    * Proteinuria ≥++ on dipstick or \\>1.0 g\u002F24 h on urine protein quantification\n12. Coagulation disorders (INR \\>1.5 or APTT \\>1.5 × ULN), bleeding tendency, or current use of thrombolytics or anticoagulants.\n\n    * Known hereditary or acquired bleeding\u002Fthrombotic conditions (e.g., hemophilia, coagulopathy, thrombocytopenia, hypersplenism).\n    * History of significant hemoptysis (≥2.5 mL\u002Fday) or massive bleeding within 2 months.\n    * Gastrointestinal bleeding, bleeding gastric ulcer, positive fecal occult blood (++ or above), vasculitis, or active bleeding within 3 months.\n    * Long-term use of warfarin\u002Fheparin or high-dose antiplatelet therapy (aspirin ≥300 mg\u002Fday or clopidogrel ≥75 mg\u002Fday).\n13. Major surgery (e.g., craniotomy, thoracotomy, or laparotomy) within 4 weeks prior to the first dose, or planned major surgery during the study period.\n14. Gastrointestinal perforation and\u002For fistula within 6 months prior to enrollment; history of arterial\u002Fvenous thrombotic events such as stroke (excluding clinically stable infarction per investigator), deep vein thrombosis, or pulmonary embolism.\n15. Unhealed wounds or fractures of clinical significance.\n16. Severe gastrointestinal conditions that may impair oral medication absorption (e.g., dysphagia, chronic diarrhea, intestinal obstruction).\n17. Severe malnutrition.\n18. Pregnant or breastfeeding women, or subjects (male or female within one year of menopause) unwilling to use effective contraception.\n19. History of substance abuse or uncontrolled psychiatric disorders.\n20. Unwilling or unable to comply with study procedures.\n21. Participation in another interventional clinical trial within 30 days prior to first dose or planning to do so during the current study.\n22. Any other condition deemed by the investigator to pose significant risk to patient safety or interfere with study conduct.",{"count":56,"type":20},88,[23,24],"The purpose of this study is to investigate the safety and efficacy of conversion therapy using HFRT combined with ICT in locally advanced or metastatic unresectable GEJA.",[27,28,60,61],"Immunotherapy","Chemotherapy",[31,32,33,63,64,65],"ORR","conversion therapy","gastroesophageal junction adenocarcinoma","2025-11-23",{"date":68,"type":40},"2025-11-28",{"date":70,"type":40},"2025-09-15",{"date":72,"type":20},"2028-05-14",{"name":46,"class":47},{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":21,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":97},"100608181","phase-2-real-world-study-of-platinum-containing-dual-drug-chemotherapy-followed-by-large-fractionated-radiotherapy-combined-withtislelizumab-in-stage-iiibc-iv-non-small-cell-lung-cancer-patient-100608181","NCT07198217","Real World Study of Platinum Containing Dual Drug Chemotherapy Followed by Large Fractionated Radiotherapy Combined withTislelizumab in Stage IIIB\u002FC-IV Non-small Cell Lung Cancer Patient","Inclusion Criteria:\n\n1. Age 18-75 years old, gender is not limited;\n2. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n3. Patients with stage IIIB\u002FC-IV non-squamous non-small cell lung cancer confirmed by cytology or histology;\n4. Tumor histology or hematology confirms no EGFR mutations and no mutations or positive driver genes for ALK, BRAF, ROS1, RET, MET, etc or Targeted drug therapy leads to drug resistance progression\n\nExclusion Criteria:\n\n1. Patients with uncontrolled autoimmune diseases;\n2. Patients who have experienced autoimmune reactions within the past 6 months and whose conditions have not improved or are unstable after corresponding treatments, such as pneumonia, thyroiditis, myocarditis, etc. that have not stabilized after treatment;\n3. Patients who have previously received systemic chemotherapy, or adjuvant or neoadjuvant therapy, and the time from the last treatment to recurrence is less than 3 months;\n4. Patients with known allergies or contraindications to the study drug or its excipients;\n5. Pregnant or lactating female patients, or female patients of childbearing potential with a positive baseline pregnancy test;\n6. Female patients of childbearing potential or male patients with reproductive plans who are unwilling to use effective contraception during the entire trial period and for 6 months after the end of the trial;\n7. Patients whose comorbidities or other conditions may affect compliance with the protocol or are deemed unsuitable for participation in this study by the investigator.","75 Years",{"count":82,"type":20},20,[24],"In clinical practice, some patients cannot tolerate concurrent chemoradiotherapy. The purpose of this study is to observe the efficacy and safety of platinum-based doublet chemotherapy followed by hypofractionated radiotherapy and Tislelizumab in patients with stage IIIB\u002FC-IV non-squamous non-small cell lung cancer. This study aims to provide more treatment options for patients with locally advanced non-small cell lung cancer.",[86,87,61,28],"NSCLC","Tislelizumab","2025-09-29",{"date":90,"type":40},"2025-09-30",{"date":92,"type":40},"2021-05-25",{"date":94,"type":20},"2027-10-10",{"name":96,"class":47},"Zibo Municipal Hospital",1,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":105,"targetDuration":4,"studyType":21,"phases":106,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":97},"100599491","phase-2-tislelizumab-combined-with-scrt-in-stage-iiibc-iv-non-squamous-non-small-cell-lung-cancera-prospective-single-arm-phase-ii-study-100599491","NCT07085182","Tislelizumab Combined With sCRT in Stage IIIB\u002FC-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Single-Arm, Phase II Study","Tislelizumab Combined With sCRT in Stage IIIB\u002FC-IV Non-Squamous Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n1. Age 18-75 years old, gender is not limited;\n2. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n3. Patients with stage IIIB\u002FC-IV non-squamous non-small cell lung cancer confirmed by cytology or histology;\n4. Patients who have not received prior systemic therapy;\n\nExclusion Criteria:\n\n1. Patients with uncontrolled autoimmune diseases;\n2. Patients who have had autoimmune reactions in the past 6 months and have not improved or are unstable despite appropriate treatment, such as untreated or unstable pneumonia, thyroiditis, myocarditis, etc.;\n3. Patients known to carry driver gene mutations such as EGFR mutation, ALK translocation, BRAF, ROS1, RET, MET, etc.;\n4. Patients who have received prior systemic therapy, or those who have received adjuvant or neoadjuvant therapy with a recurrence time of less than 3 months from the last treatment;\n5. Patients with known allergies or contraindications to the study drug or its excipients;\n6. Pregnant or lactating female patients, or female patients of childbearing potential with a positive baseline pregnancy test;\n7. Female patients of childbearing potential or male patients with reproductive plans who are unwilling to use effective contraception during the entire trial period and for 6 months after the end of the trial;\n8. Patients whose comorbidities or other conditions may affect compliance with the protocol or are deemed unsuitable for participation in this study by the investigator.",{"count":82,"type":20},[24],"In clinical practice, some patients cannot tolerate concurrent chemoradiotherapy. The purpose of this study is to observe the efficacy and safety of Tislelizumab combined with platinum-based doublet chemotherapy followed by hypofractionated radiotherapy and Tislelizumab in patients with stage IIIB\u002FC-IV non-squamous non-small cell lung cancer. This study aims to provide more treatment options for patients with locally advanced non-small cell lung cancer.",[86,87,61,28],"2025-07-17",{"date":111,"type":40},"2025-07-25",{"date":113,"type":40},"2024-01-13",{"date":115,"type":20},"2028-12-10",{"name":96,"class":47}]